Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U2CB
|
||||
| Former ID |
DNC011692
|
||||
| Drug Name |
Ibuproxam
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Respiratory disease [ICD10:J00-J99] | Withdrawn from market | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H19NO2
|
||||
| Canonical SMILES |
CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO
|
||||
| InChI |
1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)
|
||||
| InChIKey |
BYPIURIATSUHDW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| SuperDrug ATC ID |
M01AE13
|
||||
| Target and Pathway | |||||
| Target(s) | Arachidonate 5-lipoxygenase | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Resolvin D biosynthesis | |||||
| Leukotriene biosynthesis | |||||
| Lipoxin biosynthesis | |||||
| Aspirin triggered resolvin D biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Toxoplasmosis | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| Arachidonic acid metabolism | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Anti-inflammatory agents: determination of ibuproxam and its metabolite humans. Correlation between bioavailability, tolerance and chemico-physical characteristics. Arzneimittelforschung. 1980;30(9):1607-9. | ||||
| REF 2 | J Med Chem. 1987 Nov;30(11):2121-6.In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.